Altimmune Inc. (NASDAQ:ALT) and Immunomedics Inc. (NASDAQ:IMMU) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Altimmune Inc. | 3 | 3.37 | N/A | -22.68 | 0.00 |
| Immunomedics Inc. | 15 | -5932.88 | N/A | -1.38 | 0.00 |
Demonstrates Altimmune Inc. and Immunomedics Inc. earnings per share (EPS), top-line revenue and valuation.
Profitability
Table 2 provides us Altimmune Inc. and Immunomedics Inc.’s net margins, return on assets and return on equity.
| Net Margins | Return on Equity | Return on Assets | |
| Altimmune Inc. | 0.00% | -103.4% | -77% |
| Immunomedics Inc. | 0.00% | -114.5% | -56.8% |
Risk and Volatility
Altimmune Inc. is 226.00% more volatile than S&P 500 due to its 3.26 beta. Immunomedics Inc.’s 106.00% more volatile than S&P 500 which is a result of the 2.06 beta.
Liquidity
The Current Ratio and a Quick Ratio of Altimmune Inc. are 8.7 and 8.7. Competitively, Immunomedics Inc. has 15.9 and 15.9 for Current and Quick Ratio. Immunomedics Inc.’s better ability to pay short and long-term obligations than Altimmune Inc.
Analyst Ratings
Altimmune Inc. and Immunomedics Inc. Ratings and Recommendations are available in the next table.
| Sell Ratings | Hold Ratings | Buy Ratings | Rating Score | |
| Altimmune Inc. | 0 | 0 | 0 | 0.00 |
| Immunomedics Inc. | 0 | 0 | 5 | 3.00 |
Competitively the consensus target price of Immunomedics Inc. is $23.6, which is potential 58.07% upside.
Insider & Institutional Ownership
Roughly 6.8% of Altimmune Inc. shares are held by institutional investors while 89.4% of Immunomedics Inc. are owned by institutional investors. Altimmune Inc.’s share held by insiders are 2.4%. Comparatively, insiders own roughly 7.19% of Immunomedics Inc.’s shares.
Performance
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
| Performance (W) | Performance (M) | Performance (Q) | Performance (HY) | Performance (Y) | Performance (YTD) | |
| Altimmune Inc. | -11.71% | -12% | -13.44% | -28.84% | -83.08% | 28.16% |
| Immunomedics Inc. | 2.97% | -18.28% | 4.41% | -30.44% | -20.54% | 4.63% |
For the past year Altimmune Inc. was more bullish than Immunomedics Inc.
Summary
On 5 of the 8 factors Immunomedics Inc. beats Altimmune Inc.
Altimmune, Inc., a clinical stage immunotherapeutic biotechnology company, designs and develops immunotherapeutic products for treating acute respiratory infections, chronic viral infections, and cancer. The company develops NasoVAX, an intranasally administered recombinant influenza vaccine that has completed Phase I clinical trials; and HepTcell, an immunotherapy for patients chronically infected with the hepatitis B virus, which is in Phase I clinical trials. Its preclinical stage products include NasoShield, a vaccine for the prevention of anthrax disease following inhalation of pathogen spores; and Oncosyn, an immunotherapeutic for treating solid cancer indications, such as lung, colorectal, melanoma, breast, ovarian, and others. The company was formerly known as Vaxin Inc. Altimmune, Inc. was founded in 1997 and is based in Gaithersburg, Maryland.
Immunomedics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders, and other diseases. The company engages in developing antibody-drug conjugate (ADC) products comprising IMMU-132, an ADC that contains SN-38, which is in Phase II trials used for the treatment of patients with metastatic triple-negative breast cancer, and small-cell and non-small-cell lung cancers; IMMU-130, an anti-CEACAN5-SN-38 ADC that is in Phase II trials for the treatment of solid tumors and metastatic colorectal cancer; and IMMU-140 that targets HLA-DR for the potential treatment of liquid cancers. It also develops products for the treatment of cancer and autoimmune diseases, including epratuzumab, anti-CD22 antibody; veltuzumab, anti-CD20 antibody; milatuzumab, anti-CD74 antibody; and IMMU-114, a humanized anti-HLA-DR antibody. The company also provides LeukoScan, a diagnostic imaging product to determine the location and extent of infection/inflammation in bone. In addition, it offers other product candidates for the treatment of solid tumors and hematologic malignancies, as well as other diseases, which are in various stages of clinical and pre-clinical development. The company has a research collaboration with The Bayer Group to study epratuzumab as a thorium-227-labeled antibody. Immunomedics, Inc. was founded in 1982 and is headquartered in Morris Plains, New Jersey.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
